HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (30) Citing Articles via Google Scholar Google Scholar Articles by Tan, K. Articles by Wood, N. Search for Related Content PubMed PubMed Citation Articles by Tan, K. Articles by Wood, N. Social Bookmarking                         What's this?

Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities

From Clinical Pharmacology (Dr Tan, Dr Wood), Development Operations (Mr Brayshaw), Regulatory Affairs (Dr Tomaszewski), and Clinical R&D (Dr Troke), Pfizer Global Research and Development, Sandwich, Kent, United Kingdom.

This study investigated the relationship between plasma voriconazole concentrations (pVC) and risk of visual adverse events (VAEs) or liver function test (LFT) abnormalities using longitudinal logistic regression. Seven-day mean pVC were calculated from 2925 plasma samples (1053 patients); in each 7-day period, the presence or absence of VAEs/abnormal LFTs was analyzed as a binary outcome variable. There was a relationship between pVC and risk of VAE (P = .011) and a weaker, but statistically significant, association with risk of aspartate transaminase (AST), alkaline phosphatase (ALP), or bilirubin but not alanine transaminase (ALT) abnormalities. The odds ratios of LFT abnormalities per 1 µg/mL pVC increase ranged from 1.07 to 1.17. Maximum weekly occurrences were 10%, 8%, 5%, and 14% for AST, ALT, ALP, and bilirubin abnormalities, respectively. Receiver-operating characteristic curve analysis indicates that individual pVC cannot be used to predict subsequent LFT abnormalities.

Key Words: Voriconazole • visual adverse event • liver function test • plasma concentration

Address for reprints: Keith Tan, Clinical R&D (IPC 096), Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. H. Segal Aspergillosis N. Engl. J. Med., April 30, 2009; 360(18): 1870 - 1884. [Full Text] [PDF]

				D. Andes, A. Pascual, and O. Marchetti Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications Antimicrob. Agents Chemother., January 1, 2009; 53(1): 24 - 34. [Full Text] [PDF]

				A. Howard, J. Hoffman, and A. Sheth Clinical Application of Voriconazole Concentrations in the Treatment of Invasive Aspergillosis Ann. Pharmacother., December 1, 2008; 42(12): 1859 - 1864. [Abstract] [Full Text] [PDF]

				P. Liu, G. Foster, K. Gandelman, R. R. LaBadie, M. J. Allison, M. J. Gutierrez, and A. Sharma Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3617 - 3626. [Abstract] [Full Text] [PDF]

				S. Weiler, H. Zoller, I. Graziadei, W. Vogel, R. Bellmann-Weiler, M. Joannidis, and R. Bellmann Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3459 - 3460. [Full Text] [PDF]

				C. Eiden, H. Peyriere, M. Cociglio, S. Djezzar, S. Hansel, J.-P. Blayac, D. Hillaire-Buys, and for the Network of the French Pharmacovigilance Ce Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database Ann. Pharmacother., May 1, 2007; 41(5): 755 - 763. [Abstract] [Full Text] [PDF]